The expression of Fas/FasL in hepa tocellular carcinomas

World Chinese Journal of Digestology

Volumn 9, Issue 12, 2001, Pages 1364-1368

  Liang, Y ^a   Lu, B ^a   Cui, Z F ^a   Li, X D ^a   Guo, Y J ^a   Lu, Y J ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma, hepatocellular pathology; Immunohistochemistry; Liver neoplasms pathology; Membrane glycoproteins biosynthesis; RNA, messenger biosynthesis

Indexed keywords

FAS ANTIGEN; LIGAND;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METASTASIS; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035679906     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. The review of hepatology study in China
2. Current situation of gene therapy studies in inhibition of liver cancer
3. Study and progress on in vivo gene treatment of primary hepatocarcinoma
4. Drug induce the apoptosis of hepatocellular cells
5. Effect of dendritic cells on LPAK cells induced at different times in killing hepatoma cells
6. Effects of antiogenesis inhibitor TNP-470 with lipiodol in arterial embolization of liver cancer in rabbits
7. Hepatic cell apoptosis and Fas gene
8. Cell apoptosis and viral hepatitis
9. The factors affect expression of Fas in hepatocytes during chronic HBV
10. The expression of CD44/CD45 and Fas/FasL in chronic viral hepatitis
11. Fas/FasL expression and hepatocyte apoptosis on liver tissues in tupaia with HDV/HBV infection
12. Studies on Fas/FasL system in langerhans islets transplantation
13. Expression of hepatocyte apoptosis and Fas/FasL in liver tissues of patients with hepatitis D
14. Study of cellur immunity in hepatocirrhosis patients
15. The expression of Fas antigen in chronic hepatopaths
16. Apoptosis and its relationship with Fas liang expression in gastric carcinoma and its precancerous lesion
17. Perforin/Fas-liand double deficiency is associated with macrophage expansion and severe pancreatitis
18. The expression of Fas/Fasl HLA - DR in rectal cancer
19. The expression of Fas/FasL in chronic hepatitis and primary hepatocarcinomas
20. The expression of FasL in rectal cancer tissues
21. Fas/FasL expression of esophageal squamous cell carcinoma, dysplasia tissues and normal mucosa
22. Construction of eukaryotic expression vector pBK-fas and MDR reversal test of drug-resistant gastric cancer cell
23. Effects of de-N-glycosylation on the growth and expression of Fas, NM23, ICAM-1 in SMMC7721 cell line in mice
24. Human pancreatic adenocarcinomas express fas and fas ligand yet are resistant to fas-mediated apoptosis
25. Tumor-induced apopotosis of T lymphocytes: Elucidation of intracellular apoptotic events
26. Effect of combined anti-Fas mAb and IFN-γ on the induction of apoptosis in human gastric carcinoma cell line SGC-7901
27. Immunological escape mechanisms in pancreatic carcinoma
28. Altered mechanisms of apoptosis in colon cancer; Fas resistance and counterattack in the tumor-immune conflict
29. Fas ligand expression in pimary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
30. The Fas counterattack: Cancer as a site of immune pricilege
31. Functional characterization of Fas ligand on tumor cells escapting active specific immunotherapy
32. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
33. Tumor-induced apotosis of T cells: Amplification by a mitochondrial cascade
34. Tumor immunity in perforin-deficient mice: A role for CD95(Fas/APO-1)
35. Hepatocellular carcinoma cells induced apoptosis of Tlymphocytes through Fas/FasL system
36. Cutting edge: The tumor countrattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, Apo-1) pathway
37. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance
38. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
39. Fas and Fas ligand: Strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells?
40. In vivo expression of solube Fas and FAP-1: Possible michanisms of Fas resistance in human hepatoblastomas
41. Spontaneous apoptosis in advanced essphageasl carcinoma: Its relation to Fas expression
42. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma
43. Elvated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
44. The Alteration of fas receptor and ligand system in Hepatocellular carcinomas, How do hepatoma cells escape from the host immune surveillance in vivo
45. Differential role of Fas/Fas ligandinteractions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen=specific CD8 + CTL
46. Upregulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esphageal cancer
47. Frequency of apoptosis os tumor-infiltrating lymphocytes induced by Fas-counterattack in human colorectal carcinoma and its correlation with prognosis
48. Cholangioncarcinomas express Fas ligand and disable the Fas receptor
49. Prognostic signifilance of Fas and fas ligand expressions in haman esophageal
50. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
51. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity